Home >> Signaling Pathways >> Apoptosis >> PD-1/PD-L1 interaction

PD-1/PD-L1 interaction(PD-1/PD-L1 相互作用)

Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

  1. Cat.No. 产品名称 Information
  2. GC25160 BMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
  3. GC68404 Human PD-L1 inhibitor IV
  4. GC67694 PD-1/PD-L1-IN-9 hydrochloride
  5. GC66394 Penpulimab
  6. GC66378 Serplulimab
  7. GC66344 Envafolimab
  8. GC66337 Anti-Mouse PD-L1 Antibody
  9. GC65920 PD1-PDL1-IN 1
  10. GC65580 Sugemalimab
  11. GC65290 Sintilimab Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
  12. GC65266 Onvatilimab
  13. GC65071 PD-1/PD-L1-IN 3 TFA
  14. GC65033 Tislelizumab
  15. GC64855 PD-1/PD-L1-IN-23
  16. GC64561 Toripalimab
  17. GC63984 PD-L1-IN-1
  18. GC63517 PD-1-IN-24
  19. GC62688 PD-1/PD-L1-IN-8 INCB086550 (PD-1/PD-L1-IN-8) is potent a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.
  20. GC62682 BMSpep-57 hydrochloride
  21. GC62658 PD-1/PD-L1-IN 7
  22. GC62502 PD-1/PD-L1-IN-NP19 A PD-1/PD-L1 interaction inhibitor
  23. GC62387 PD-1/PD-L1-IN-9
  24. GC62253 Camrelizumab Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.
  25. GC62125 PD-1/PD-L1-IN-10
  26. GC61946 TPP-1
  27. GC50482 (D)-PPA 1 An inhibitor of the PD-1-PD-L1 protein-protein interaction
  28. GC38740 BMS-1001 hydrochloride An inhibitor of the PD-1/PD-L1 interaction
  29. GC38131 BMS-1166 hydrochloride A PD-1/PD-L1 interaction inhibitor
  30. GC38044 Fraxinellone A liminoid degradant with diverse biological activities
  31. GC36862 PD-1-IN-22
  32. GC36768 NP-12 (TFA)
  33. GC36767 NP-12 A PL-1/PD-L interaction inhibitor
  34. GC35913 Durvalumab Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
  35. GC19531 Pembrolizumab

    Pembrolizumab (MK-3475) 是一种人源化 IgG4 抗体,可抑制程序性细胞死亡 1 (PD-1) 受体,用于癌症免疫治疗。

  36. GC34929 PD-1-IN-17 TFA An inhibitor of PD-1 signaling
  37. GC34928 PD-1-IN-17 An inhibitor of PD-1 signaling
  38. GC34218 Nivolumab (BMS-936558) Nivolumab (BMS-936558) 是一种程序性死亡受体-1 (PD-1) 阻断人 IgG4 抗体,用于治疗晚期(转移性)非小细胞肺癌。
  39. GC32704 Atezolizumab (MPDL3280A)

    Atezolizumab (MPDL3280A) (MPDL3280A) 是一种针对程序性死亡配体 1 (PD-L1) 的选择性人源化单克隆 IgG1 抗体,用于癌症研究。

  40. GC31878 PD1-IN-2
  41. GC31753 BMS-1166 (PD-1/PD-L1-IN1)

    A PD-1/PD-L1 interaction inhibitor

  42. GC31719 Avelumab (Anti-Human PD-L1, Human Antibody) Avelumab (anti-PD-L1) (Bavencio, MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
  43. GC19225 PD-1-IN-1 (CA-170) PD-1-IN-1 (CA-170) 是一种口服给药的 VISTA 和 PD-L1 双重抑制剂。
  44. GC19131 Tomivosertib A potent inhibitor of MNK1 and MNK2
  45. GC16258 PD-1/PD-L1 Inhibitor 3 A PD-1/PD-L1 interaction inhibitor
  46. GC15142 PD-1/PD-L1 inhibitor 1 (BMS-1) A PD-1/PD-L1 interaction inhibitor
  47. GC16762 PD-1/PD-L1 inhibitor 2 A PD-1/PD-L1 interaction inhibitor
  48. GC10469 Sulfamethoxypyridazine A sulfonamide antibiotic

47 Item(s)

per page

Set Descending Direction